Current guidelines for treatment in East Asia 2022: Differences among China, Japan, and South Korea.

() infection is highly prevalent in East Asia. The overall seroprevalence rate of infection is 44.2% in China, 37.6%-43.2% in Japan, and 51.0% in South Korea. can cause peptic ulcer disease and gastric cancer. East Asian countries have high rates of gastric cancer (age-standardized incidence rate: 20-30 per 100000). The Kyoto global consensus report emphasized that gastritis should be considered the main cause for the development of gastric cancer. treatment guidelines in China, Japan, and South Korea have recently been revised according to data from each of those countries. However, emerging antibiotic resistance is an important barrier to eradication. The recommended treatment regimens differ among those three East Asian countries. In this review, recent guidelines and up-to-date research on treatment regimens from China, Japan, and South Korea are discussed.